PAEDIATRIC HOSPITAL LEVEL ESSENTIAL MEDICINES LIST CHAPTER 5: DERMATOLOGY NEMLC 30 JUNE 2016
|
|
- Dominick Taylor
- 5 years ago
- Views:
Transcription
1 PAEDIATRIC HOSPITAL LEVEL ESSENTIAL MEDICINES LIST CHAPTER 5: DERMATOLOGY NEMLC 30 JUNE 2016 PICTURES OF CONDITIONS: The Paediatric Expert Review Committee (ERC) recommended that the Dermatology Chapter include photographs of various dermatological conditions. New Standard Treatment Guideline - Cutaneous Haemangiomas The Paediatric ERC recommended the addition of a section on cutaneous haemangiomas in the Dermatology Chapter. The following section was added: CUTANEOUS HAEMANGIOMAS D18.0 DESCRIPTION Benign tumours of the vascular endothelium that may be classified as either infantile or congenital.» Infantile haemangiomas: vascular neoplasms characterised by abnormal proliferation of endothelial cells and abnormal blood vessel architecture. Usually appear before 4 weeks of age and continue to grow, with most completing their growth by 5 months.» Congenital haemangiomas: fully grown at birth, and are either rapidly involuting or non-involuting. DIAGNOSTIC CRITERIA» Physical examination.» Most haemangiomas can be diagnosed clinically. GENERAL AND SUPPORTIVE MEASURES» Counseling to assist patient in dealing with the condition. MEDICINE TREATMENT Treatment with propranolol recommended for:» Life-threatening haemangiomas (airways),» Function-threatening haemangiomas,» Ulcerating lesions. Pre-treatment evaluation: Ensure no cardiac or pulmonary abnormalities.» Minimum baseline assessment: o Full clinical history and examination. o Baseline heart rate, blood pressure and oxygen saturation. o ECG (Only in patients where there are concerns of cardiovascular disease).» Propranolol, oral: o Initial dose: 0.5 mg/kg/dose, 12 hourly for 7 days; o Then: 1 mg/kg/dose, 12 hourly for 7 days; o Then: 1.5 mg/kg/dose, 12 hourly for 6 months.
2 o Discontinue over 2 weeks as for initiation. REFERRAL Diagnostic uncertainty. Failure to respond to therapy. Peri-ocular haemangioma. Suspected airway haemangioma. Large segmental haemangioma on face or neck for echocardiogram MEDICINE AMENDMENTS SECTION MEDICINE ADDED/DELETED/NOT ADDED Staphalococcal scalded skin syndrome Oral medicine treatment Flucloxacillin Dose amended Medicine treatment Pain management Referral added to the Pain Control and Palliative Care in Paediatrics Chapter Erythema Multiform/Stevens-Johnson Syndrome Dressings Dressings guidance Added Antibiotic therapy Flucloxacillin Added Drug Reactions Antihistamines Cetirizine Dose amended Chlorphenamine Age specification added Maximum dose added Promethazine Maximum dose added Acne Topical retinoids Class Cellulitis and Erysipelas Peri-orbital cellulitis Ceftriaxone/ cefotaxime Moved to eye chapter Non-severe disease Flucloxacillin Added Penicillin allergy Erythromycin Deleted Azithromycin Added Eczema Antihistamine Cetirizine Dose amended Chlorphenamine Age specification added Maximum dose added Urticaria Severe chronic urticaria Cetirizine Dose amended Cutaneous Haemangiomas Medicine treatment Propranolol Added
3 5.1.2 Stapholococcal scalded skin syndrome Flucloxacillin - dose amended Pain management - referral added The Paediatric ERC recommended that the lower range dose be removed and the dose recommendation be 25 mg/kg/dose, in line with the British National Formulary for Children. 1» Flucloxacillin, oral, mg/kg/dose 6 hourly for 7 days. The Paediatric ERC recommended that pain management would be important to include in the staphylococcal scalded skin syndrome section. It was recommended that a referral to the Pain Control and Palliative Care in Paediatrics Chapter be added. The following text was added: For Pain Management: Refer to Chapter 20: Pain Control and Palliative Care in Paediatrics Erythema Multiform/Stevens-Johnson Syndrome Dressings: added Flucloxacillin: added The Paediatric ERC agreed that it would be beneficial to add recommendations on use of dressings that were aligned with the Adult Hospital Level STGs and EML. 2 The following text was added: Dressings Skin hygiene, daily cleansing and bland, non-adherent dressings as needed. Do not use silver sulfadiazine if Stevens Johnsons Syndrome is thought to be due to cotrimoxazole or other sulphonamide Cephalexin was the only recommended oral agent for use in Erythema multiform/stevens-johnson Syndrome. During previous review of the Paediatric Standard Treatment Guidelines (STGs) and Essential Medicines List (EML), cephalexin was included in place of flucloxacillin as a result of previous medicine availability problems with flucloxacillin. The Paediatric ERC recommended that flucloxacillin should be included as the oral alternative to cloxacillin. 1 The British National Formulary for Children BMJ Group, Pharmaceutical Press, RCPCH Publication Ltd. 2 National Department of Health. Adult Hospital Level Standard Treatment Guidelines and Essential Medicines List
4 Use IV antibiotics if the oral route cannot be used.» Cloxacillin, IV, 50 mg/kg/dose 6 hourly. OR» Flucloxacillin, oral, 25mg/kg/dose 6 hourly. OR (if flucloxacillin is unavailable)» Cephalexin, oral, mg/kg/dose 6 hourly Drug Reactions Cetirizine: dose amended Chloramphenicol: Age specifications added, maximum dose added Promethazine: Maximum dose added The cetirizine package insert 3 and the SAMF 4 recommend dosing cetirizine from 2 years of age. The Paediatric ERC recommended that the cetirizine dosing be aligned with both the SAMF and package insert. For children 3 2 years and older:» Cetirizine, oral, as a single dose at night. o Children years: 5 mg. o Children > years: 10 mg. The Paediatric ERC recommended that the use of chlorphenamine should be specified for use in children less than 2 years where cetirizine can not be used. For children less than 2 years Where the oral route can be used:» Chlorphenamine, oral, 0.1mg/kg/dose as a single dose at night. (Maximum 4mg). A maximum dose for promethazine was included. Where the oral route cannot be used:» Promethazine, IV, 0.1 mg/kg/dose 8 12 hourly. (Maximum 25mg) Acne Topical retinoids: Class added 3 Allecet Syrup package insert. Cipla Life Sciences (Pty)Ltd April South African Medicines Formulary. 11th Edition. Division of Clinical Pharmacology. University of Cape Town. 2014
5 During scoping, adapalene was investigated for the management of acne as an alternative to topical tretinoin. Topical adapalene has shown to be better tolerated than tretinoin (currently the recommended topical retinoid in the Paediatric STGs and EML), however these studies were based on older formulations of tretinoin. 5 The Paediatric ERC recommended that topical retinoids be declared a therapeutic class, with either tretinoin or adapalene included as members of this class. The text was amended to indicate the topical retinoid class: Topical retinoid, e.g.: Tretinoin cream/gel 0.05%, topical, applied sparingly once daily at bedtime until substantial improvement Cellulitis and Erysipelas Peri-orbital cellulitis Treatment: Moved to Eye Chapter Flucloxacillin: added Erythromycin: Deleted Azithromycin: Added The Paediatric ERC recommended that the management of peri-orbital cellulitis be moved to the Eye chapter. As previously discussed flucloxacillin was added as the oral alternative to cloxacillin in addition to cephalexin. In line with the National Essential Medicines List Committee (NEMLC) meeting January 2015, where it was recommended that the macrolide erythromycin be replaced with clarithymycin or azithromycin, erythromycin was deleted, and replaced with azithromycin, for penicillin allergy. Penicillin allergy Macrolide, e.g.: Erythromycin, oral, Azithromycin, oral 10 mg/kg/day, 6 hourly for 5 3 day Eczema Cetirizine: dose amended Chlorphenamine: age specifications added, maximum dose added 5 Zaenglein AI, et. al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016; 74:
6 As previously discussed, cetirizine dose was amended and recommended for age 2 years and above, while chlorphenamine was recommended for use in children under 2 years. For children 2 years and older:» Cetirizine, oral, as a single dose. o Children 2-6 years: 5 mg. o Children 6-12 years: 10 mg. For children less than 2 years:» Chlorphenamine, oral, 0.1mg/kg/dose as a single dose at night. (Maximum 4mg) Urticaria Cetirizine: dose amended Cetirizine dose amended as discussed above. For children 2 years and older:» Cetirizine, oral, as a single dose. o Children 2-6 years: 5 mg. o Children 6-12 years: 10 mg. Cetirizine, oral, as a single dose at night. o Child 3 12 years: 5 mg. o Child > 12 years: 10 mg Cutaneous Haemangiomas Propranolol: added A section on cutaneous haemangiomas was added to the Dermatology Chapter. Propranalol was added as the medication treatment for life-threatening haemangiomas (airways), function-threatening haemangiomas and ulcerating lesions. 6, 7, Propranolol has been demonstrated to be a safe and effective treatment for infantile haemangiomas. 8, 9 A randomised controlled trial including 40 children between the ages of 9 weeks and 5 years 6 Solman L, Murabit A, Gnarra M, Harper JI, Syed SB, Glover M. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. Arch Dis Child. 2014; 99: Zimmermann AP, Wiegand S, Werner JA, Eivazi. Propranolol therapy for infantile haemangiomas: Review of the literature. International Journal of Pediatric Otorhinolaryngology. 2010; 74:
7 randomly assigned patients to either propranolol or placebo. Infantile haemangioma growth stopped by week 4 in the propranalol group, with significant changes in volume seen between the groups at week 12 [difference (95% CI to -5.2), P = 0.03]. There were significant improvements in redness and elevation as based on investigator scores from clinical photographs at weeks 12 and 24 (P = 0.07 and P=0.01 respectively for redness, and P= and P= 0.01 for elevation. 9 The following text was added: Treatment with propranolol recommended for:» Life-threatening haemangiomas (airways),» Function-threatening haemangiomas,» Ulcerating lesions. Pre-treatment evaluation: Ensure no cardiac or pulmonary abnormalities.» Minimum baseline assessment: o Full clinical history and examination; o Baseline heart rate, blood pressure and oxygen saturation; o ECG (Only in patients where there are concerns of cardiovascular disease).» Propranolol, oral: o Initial dose: 0.5 mg/kg/dose, 12 hourly for 7 days; o Then: 1 mg/kg/dose, 12 hourly for 7 days; o Then: 1.5 mg/kg/dose, 12 hourly for 6 months. o Discontinue over 2 weeks as for initiation. 8 Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: An update of pathogenesis and therapy. Pediatrics. 2013; 131: Hogeling M, Adams S, Wargon O. A Randomized Controlled Trial of Propranolol for Infantile Hemangiomas. Pediatrics. 2011; 128:e259-e266.
Clinical profile of skin diseases in accident and emergency department attenders
Hong Kong J. Dermatol. Venereol. (2007) 15, 4-9 Original Article Clinical profile of skin diseases in accident and emergency department attenders CY Chan, KL Kam, CA Graham, TH Rainer, NM Luk Skin problems
More informationLymphoedema in Wales - Mixing Oedema and Infection
Lymphoedema in Wales - Mixing Oedema and Infection Melanie Thomas Karen Morgan 5/6/2014 1 National Clinical Lead Lymphoedema National Education & Research Lymphoedema Specialist Lymphoedema: Photographs
More informationInfantile Hemangiomas: Not Just Strawberries
Infantile Hemangiomas: Not Just Strawberries Ilona J. Frieden M.D. Professor of Dermatology & Pediatrics UC San Francisco Conflict of Interests: Consultant: Pierre Fabre Off-label discussion: I do intend
More informationDrug Allergy A Guide to Diagnosis and Management
Drug Allergy A Guide to Diagnosis and Management (Version 1 April 2015 updated April 2018) Author: Jed Hewitt Chief Pharmacist, Governance & Professional Practice Date of Preparation: April 2015 Updated:
More informationPAEDIATRIC ACUTE CARE GUIDELINE. Impetigo. This document should be read in conjunction with this DISCLAIMER
Princess Margaret Hospital for Children PAEDIATRIC ACUTE CARE GUIDELINE Impetigo Scope (Staff): Scope (Area): All Emergency Department Clinicians Emergency Department This document should be read in conjunction
More informationACNE VULGARIS: DIAGNOSIS AND TREATMENT
ACNE VULGARIS: DIAGNOSIS AND TREATMENT Federal Bureau of Prisons Clinical Guidance DECEMBER 2017 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of
More informationACNE UPDATE 2017 FACULTY DISCLOSURE ACNE UPDATE
ACNE UPDATE 2017 PATRICIA TREADWELL, M.D. PROFESSOR OF PEDIATRICS AND DERMATOLOGY IU SCHOOL OF MEDICINE FACULTY DISCLOSURE I have no relevant financial relationships with the manufacturer(s) of any commercial
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: 383 814-6) Tube of 60 g (CIP code: 383 816-9) Applicant: GALDERMA
More informationSummary of the risk management plan (RMP) for Hemangiol (propranolol)
EMA/122592/2014 Summary of the risk management plan (RMP) for Hemangiol (propranolol) This is a summary of the risk management plan (RMP) for Hemangiol, which details the measures to be taken in order
More informationEuropean Medicines Agency decision
EMA/795938/2012 European Medicines Agency decision P/0004/2013 of 21 January 2013 on the acceptance of a modification of an agreed paediatric investigation plan for propranolol hydrochloride (EMEA-000511-PIP01-08-M04)
More informationNew product information wording Extracts from PRAC recommendations on signals
12 October 2017 EMA/PRAC/610988/2017 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 25-29 September 2017
More informationSWISS SOCIETY OF NEONATOLOGY. Multiple infantile hemangiomas in a preterm infant
SWISS SOCIETY OF NEONATOLOGY Multiple infantile hemangiomas in a preterm infant November 2017 Heschl K, Romaine Arlettaz R, Department of Neonatology (HK, AR), University Hospital Zurich, Switzerland Title
More informationUndergraduate Dermatology Curriculum July 2016
Undergraduate Dermatology Curriculum July 2016 British Association of Dermatologists Introduction This document is the 2016 revised dermatology undergraduate curriculum (UK) from the British Association
More informationPropranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol
Editor s choice Scan to access more free content 1 Department of Dermatology, Great Ormond Street Hospital for Children, London, UK 2 Department of Plastic and Reconstructive Surgery, Great Ormond Street
More informationReview Acne Pathogenesis Clinical Evaluation Treatment Guidelines
Tiffany Herd, MD Pediatric Dermatology Fellow Baylor College of Medicine/Texas Children's Hospital Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Psychosocial Impact of Acne Acne is
More informationThe management of chronic urticaria in primary care for adults and children
The management of chronic urticaria in primary care for adults and children September Version 2.0 This supersedes version 1.0 Review due in September 2019 Document location DOCUMENT CONTROL Copies of this
More informationDuring the last 20 years, the number of topical
THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Compared With Tretinoin Microsphere 0.04% and 0.1% Jonathan S. Dosik, MD; Kenneth Homer, MS; Stéphanie Arsonnaud
More informationAnnex III. Amendments to relevant sections of the product information
Annex III Amendments to relevant sections of the product information Note: These amendments to the relevant sections of the Summary of Product Characteristics and Package Leaflet are the outcome of the
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the
More informationACNE BOOT CAMP TOPICAL THERAPY BASICS
ACNE BOOT CAMP TOPICAL THERAPY BASICS Lawrence J Green, MD Associate Clinical Professor of Dermatology George Washington University School of Medicine Washington DC Relevant Disclosures Investigator -Allergan,
More informationAmendments to the Schedule of Benefits for Physician Services - Effective April 1, 2012
To: Published By: Physicians and Hospitals Health Services Branch Date Issued: May 7, 2012 Bulletin #: 4561 Re: Amendments to the Schedule of Benefits for Physician Services - Effective April 1, 2012 In
More informationEichenfield: Neonatal Dermatology
What You Need to Know about Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Disclosures
More informationPaediatric Dermatology. What s New? Stephanie Menzies
Paediatric Dermatology. What s New? Stephanie Menzies Atopic Dermatitis Emollients in the newborn Randomised controlled trial in US & UK 124 neonates high risk for AD Full body emollient at least daily
More informationBeta-blockers in the Treatment of Infantile Hemangiomas 5yrs experience
Beta-blockers in the Treatment of Infantile Hemangiomas 5yrs experience Josef Mališ V.Stará, S.Klovrzová, L.Nováková, M.Kynčl, A.Sukop, B.Kocmichová, Š.Čapková, K.Bláhová Dept. of Pediatric Hematology/Oncology
More informationDESCRIPTIONS FOR MED 3 ROTATIONS Dermatology A3S
Regardless of your future field of practice, you will be exposed to a considerable amount of dermatology and this rotation provides you the chance to see a range of skin diseases. You will have the opportunity
More informationPriority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
More informationL. Montero. Carrera 16# , Consultorio 303, Santafe de Bogotd, D.C., Colombia
Journal of Antimicrobial Chemotherapy (1996) 37, Suppl. C, 125-131 A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin
More informationPROCEEDINGS PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP
PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP A HEALTHY 4-WEEK-OLD INFANT WITH ACNE A 4-week-old infant was brought to the pediatrician s office by his parents following the appearance
More informationNEXAVAR (sorafenib tosylate) oral tablet
NEXAVAR (sorafenib tosylate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCiclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong
ORIGINAL ARTICLES Ciclosporin Microemulsion for Severe Atopic Dermatitis: Experience on Adolescents and Adults in Hong Kong Drs. H. F. Ho, L.Y. Chong, K. M. Ho and W. K. Fung Social Hygiene Service (Dermatology),
More informationDiagnosis and Treatment of Respiratory Illness in Children and Adults Guideline
Member Groups Requesting Changes: Lakeview Clinic Marshfield Clinic Mayo Clinic South Lake Pediatrics Response Report for Review and Comment January 2013 Diagnosis and Treatment of Respiratory Illness
More informationSubject Outline: Dermatology II
Subject Outline: Dermatology II Course: Master of Dermatology (Coursework) Subject: Dermatology II (An introduction to clinical dermatology) Credit Points: 3 Year/Semester Delivered: 1/2 Subject Outline:
More informationRegulatory Status FDA approved indication: Tretinoin products are indicated for the topical treatment of acne vulgaris (5-16).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.03 Subject: Tretinoin Page: 1 of 5 Last Review Date: September 15, 2017 Tretinoin Description Atralin
More informationEmergency Dermatology Dr Melissa Barkham
Emergency Dermatology Dr Melissa Barkham Spotlight Seminar 30 th September 2010 Why is this important? Urgent recognition and treatment of dermatologic emergencies can be life saving and prevent long term
More informationLawrence F. Eichenfield, M.D.
What s New in Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence F.
More informationPatient Group Direction for Doxycycline (Tetracycline) Version: 01 Start Date: October 2015 Expiry Date: October 2018
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG Lancashire North CCG Fylde & Wyre CCG East Lancashire CCG Change history Version
More informationANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS GIT PRODUCTS
SR. NO 1 ANTI COLD / ANTI ALLERGIC / ANTI-ASTHMATICS Paracetamol 500 mg, Phenylephrine HCL 5 mg With Chlorpheniramine Maleate 2 mg & Caffeine 30 mg Tablets 2 Salbutamol Tablets BP 2 mg 3 Salbutamol Tablets
More informationEverant.in/index.php/jmpr. Journal of Medical Practice and Review
Everant.in/index.php/jmpr Journal of Medical Practice and Review Real world Efficacy and Tolerance of Bepotastine, a new 2 nd generation antihistamine, in Pruritis and other symptoms associated with cutaneous
More informationGLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations q
The British Association of Plastic Surgeons (2005) 58, 348 352 GLUT-1: an extra diagnostic tool to differentiate between haemangiomas and vascular malformations q J. Leon-Villapalos a, K. Wolfe b, L. Kangesu
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationQuick Reference Guide SUPPORTED BY:
Quick Reference Guide SUPPORTED BY: 1 The recommendations in this publication do not indicate an exclusive course of treatment or serve as a standard of care. Variations, taking into account individual
More informationObjectives. 1. Recognizing benign skin lesions. 2.Know which patients will likely need surgical intervention.
The Joy of Pediatric Skin Dr. Claire Sanger University of Kentucky Plastic & Reconstructive Surgery Objectives 1. Recognizing benign skin lesions 2.Know which patients will likely need surgical intervention.
More informationManaging Penicillin Allergy
Managing Penicillin Allergy Brian T. Kelly, MD MA April 12, 2019 Objectives Review penicillin allergy prevalence, morbidity, and management Describe the penicillin testing and oral challenge process Provide
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for budesonide,
More informationFusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P
Fusidic acid and erythromycin in the treatment of skin and soft tissue infection: a double blind study Wall A R, Menday A P Record Status This is a critical abstract of an economic evaluation that meets
More informationObjectives. Routine to Rare: Complex Wound and Skin Conditions 8/29/2017
Routine to Rare: Complex Wound and Skin Conditions Debbie Harrell RN, MSN Objectives Describe various pediatric complex wound and skin conditions. Identify the root causes of complex wound and skin conditions
More informationMultiple Drug Allergies
Management of Patients with Multiple Drug Allergies Roland Solensky, MD, FAAAAI The Corvallis Clinic Corvallis, OR roland.solensky@corvallisclinic.com Conflict of Interest Financial: None Research: Merck,
More informationIressa. Iressa (gefitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Iressa Page: 1 of 5 Last Review Date: June 22, 2018 Iressa Description Iressa (gefitinib) Background
More informationAnaphylaxis School First results of a national multicenter study
Anaphylaxis School First results of a national multicenter study J. Kupfer, S. Schallmayer, I. Fell, U. Gieler for the German study group Anaphylaxis is an acute, potentially life-threatening hypersensitivity
More informationTherapeutic Effect of Propranolol in Mexican Patients with Infantile Hemangioma
Drugs - Real World Outcomes (2016) 3:25 31 DOI 10.1007/s40801-015-0052-3 ORIGINAL RESEARCH ARTICLE Therapeutic Effect of Propranolol in Mexican Patients with Infantile Hemangioma Saul Castaneda 1,3 Esbeydy
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392
Adalimumab for treating moderate to severe ere hidradenitis suppurativa Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta392 NICE 2018. All rights reserved. Subject to Notice
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationEuropean Medicines Agency decision
EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)
More informationOral Antibacterial Therapy for Acne Vulgaris: An Evidence- Based Review
Am J Clin Dermatol DOI 10.1007/s40257-017-0267-z EVIDENCE-BASED REVIEW Oral Antibacterial Therapy for Acne Vulgaris: An Evidence- Based Review Amanda Bienenfeld 1 Arielle R. Nagler 2 Seth J. Orlow 2 Springer
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationEpidemiological Update Diphtheria
Epidemiological Update Diphtheria 16 April 2018 Diphtheria in the Americas - Summary of the situation In 2017, four countries in the Region of the Americas Brazil, the Dominican Republic, Haiti, and the
More informationAnnex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)
Annex I Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s) 1 Scientific conclusions Taking into account the PRAC Assessment Report on the PSUR(s) for dexamethasone
More informationTopical Retinoids Prior Authorization Criteria Program Summary
Topical Retinoids Prior Authorization Criteria Program Summary OBJECTIVE The intent of the Retinoids Prior Authorization (PA) criteria is to discourage use of the listed target agents for the treatment
More informationPrevalence and pattern of adverse cutaneous drug reactions presenting to a tertiary care hospital
International Journal of Research in Dermatology Janardhan B et al. Int J Res Dermatol. 2017 Mar;3(1):74-78 http://www.ijord.com Original Research Article DOI: http://dx.doi.org/10.18203/issn.2455-4529.intjresdermatol20164248
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationPaediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension
5 December 2011 EMA/CHMP/213972/2010 Committee for Medicinal Products for Human use (CHMP) Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of
More informationEvaluation of hemangioma management in Erbil city
Evaluation of hemangioma management in Erbil city Received: 30/9/2013 Accepted: 30/1/2014 Introduction Jalal Hamasalih Fattah * Wesam Amjad Kaka ** Abstract Background and objective: The term hemangioma
More informationTable 1: Guideline data collection
Table 1: Guideline data collection Guideline table Arguments Key Guideline number Numerical number to allocate the. Numerical number Filenames File name of the record. e.g. G0001.csv Guideline name Identity
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
Doxycycline/Minocycline Step Therapy Criteria Program Summary Step therapy applies to Commercial and Health Insurance Marketplace formularies only. OBJECTIVE The intent of the Doxycycline/Minocycline Step
More informationSetting The setting was outpatient departments of referral hospitals. The economic analysis was conducted in India.
Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial ISCAP study group Record Status This is a critical abstract of
More informationFood allergy in children. nice bulletin. NICE Bulletin Food Allergy in Chlidren.indd 1
nice bulletin Food allergy in children NICE provided the content for this booklet which is independent of any company or product advertised NICE Bulletin Food Allergy in Chlidren.indd 1 23/01/2012 11:04
More informationAWMA MODULE ACCREDITATION. Module Six: Management of Oncology Related and Palliative Wounds
AWMA MODULE ACCREDITATION Module Six: Management of Oncology Related and Palliative Wounds Introduction- The Australian Wound Management Association Education & Professional Development Sub Committee-(AWMA
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationפורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר SUMMARY OF PRODUCT CHARACTERISTICS
פורמט עלון זה נקבע ע"י משרד הבריאות ותוכנו נבדק ואושר SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT FELDENE GEL 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram contains 5mg
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with skin lesions are receiving appropriate Primary Care for their lesions POLICY All DOP Primary Care Providers are expected to follow this guideline and/or
More informationNational Horizon Scanning Centre. Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids.
Mepolizumab (Bosatria) for hypereosinophilic syndrome first line in combination with corticosteroids May 2008 This technology summary is based on information available at the time of research and a limited
More informationTreatment of infantile hemangioma with topical imiquimod 5% cream
Original Article Treatment of infantile hemangioma with topical imiquimod 5% cream Hassan Seirafi, MD Amirhooshang Ehsani, MD Shabboo Jesri, MD Fatemeh Gholamali, MD Pedram Noormohammadpour, MD Department
More informationANTIBIOTICS ACUTE RHINOSINUSITIS IN CHILDREN
MARCH 2016 DRUG ANTIBIOTICS This optimal usage guide is mainly intended f primary care health professionnals. It is provided f infmation purposes only and should not replace the clinician s judgement.
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationDermatology GP Referral Guidelines
Austin Health Dermatology Department holds 5 Clinic sessions to discuss and plan the treatment of with Dermatology conditions. Department of Health clinical urgency categories for specialist clinics Urgent:
More informationPRODIGY Quick Reference Guide
PRODIGY Quick Venous leg ulcer infected How do I assess a venous leg ulcer? Chronic venous insufficiency and venous hypertension result from damage to the valves in the veins of the leg and inadequate
More informationUSAID Health Care Improvement Project. pneumonia) respiratory infections through improved case management (amb/hosp)
Improvement objective: : decrease morbidity and mortality due to acute upper (rhinitis, sinusitis, pharyngitis) and lower (bronchitis, pneumonia) respiratory infections through improved case management
More informationJOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN
JOINT WHO/UNAIDS/UNICEF STATEMENT ON USE OF COTRIMOXAZOLE AS PROPHYLAXIS IN HIV EXPOSED AND HIV INFECTED CHILDREN WHO, UNAIDS and UNICEF, guided by recent evidence, have agreed to modify as an interim
More informationAZITHROMYCIN 250 MG TREATMENT FOR TOOTHACHE PAIN RELIEF
AZITHROMYCIN 250 MG TREATMENT FOR TOOTHACHE PAIN RELIEF Azithromycin 250 Mg Treatment For Toothache Pain Relief Seeing azithromycin 250 mg Azithromycin tablets ip 500 mg for acne Does azithromycin affect
More informationClarity around the new editions of the BNF Publications
Clarity around the new editions of the BNF Publications UKMi, the Neonatal and Paediatrics Pharmacy Group (NPPG) and the BNF are aware of a number of discussions and email threads discussing BNF for Children
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 12 September 2007 INFRACYANINE 25 mg/10 ml, powder and solvent for solution for injection 25 mg vial with one 10 ml
More informationPart VI: Summary of the risk management plan by product
Version 1.3, 28-Dec-2015 Risk Management Plan of a fixed combination of Dexketoprofen trometamol and Tramadol hydrochloride (oral formulation) Part VI: Summary of the risk management plan by product VI.1
More informationPediatric Dermatology
Pediatric Dermatology --------- Emergencies & Urgencies Nicholas V. Nguyen, M.D. Director, Pediatric Dermatology Disclosures In the past 12 months, I have had the following financial relationships with
More informationAnnex II. Scientific conclusions
Annex II Scientific conclusions 5 Scientific conclusions Beclometasone dipropionate (BDP) is a glucocorticoid and a prodrug of the active metabolite, beclometasone-17-monopropionate. Beclometasone dipropionate
More informationNon-Beta-lactam Antibiotic: Testing and Desensitization
Non-Beta-lactam Antibiotic: Testing and Desensitization David A. Khan, MD Professor of Medicine Allergy & Immunology Program Director Division of Allergy & Immunology 1 Disclosures n Research Grants n
More information(galsulfase) DOSING & ADMINISTRATION GUIDE
(galsulfase) DOSING & ADMINISTRATION GUIDE Indication: (galsulfase) is indicated for patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). has been shown to improve walking and stair-climbing
More informationUpdate on Pediatric Vascular Tumors
Update on Pediatric Vascular Tumors Jim Treat, MD Associate Professor of Clinical Pediatrics and Dermatology No Relevant Conflicts of Interest PHOTOGRAPHY & VIDEOTAPING ARE STRICTLY PROHIBITED IN ALL EDUCATIONAL
More informationSkin Manifestations of Drug Reactions
Skin Manifestations of Drug Reactions Dr Carol Hlela, Division of Dermatology Department of Medicine, University of Cape Town and Red Cross Children s Hospital What are the Skin Manifestations of Drug
More informationStarship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles
Starship Paediatric Respiratory and Sleep Medicine Department Outpatient Referral Criteria General Principles This document provides guidance for elective outpatient referrals to the Starship Tertiary
More informationCETUXIMAB Single agent with radiotherapy. PROCEDURE REF: MPHACETUX (Version No: 1.0)
Systemic Anti Cancer Treatment Protocol CETUXIMAB Single agent with radiotherapy PROCEDURE REF: MPHACETUX (Version No: 1.0) Approved for use in: Locally advanced squamous cell cancer of the head and neck
More informationUpdate on Vascular Tumors
Update on Vascular Tumors Deepti Gupta, MD Assistant Professor Department of Pediatrics and Division of Dermatology Seattle Children s Hospital University of Washington School of Medicine PHOTOGRAPHY &
More informationAcne is one of the most common skin diseases. It usually occurs during adolescence, but can
DOI: 10.5124/jkma.2010.53.7.623 pissn: 1975-8456 eissn: 2093-5951 http://jkma.org Pharmacotherapeutics Pharmacologic Treatment of Acne Dae Hun Suh, MD Department of Dermatology, Seoul National University
More informationCommon Drug Review Pharmacoeconomic Review Report
Common Drug Review Pharmacoeconomic Review Report March 2017 Drug Indication Reimbursement request Dosage form(s) Propranolol hydrochloride (Hemangiol) For the treatment of proliferating infantile hemangioma
More informationClinical Policy Bulletin: Infantile Hemangioma
Infantile Hemangioma Page 1 of 13 Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Clinical Policy Bulletin: Infantile Hemangioma Revised April 2014 Number:
More informationPediatric Medication Calculations
SECTION 7 Pediatric Medication Calculations CHAPTER 0 Pediatric Oral and Parenteral Medications CHAPTER Pediatric Intravenous Medications 00 Cengage Learning. All Rights Reserved. May not be scanned, copied
More informationFuture of Pediatrics: Blisters, Hives and Other Tales from the Emergency Room June 14 th, 2016
A. Yasmine Kirkorian MD Assistant Professor of Dermatology & Pediatrics Children s National Health System George Washington University School of Medicine & Health Sciences Future of Pediatrics: Blisters,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Minocycline ER (Solodyn) and Microspheres (Arestin) Reference Number: CP.PMN.80 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan See Important Reminder
More informationTo order reprints or e-prints of JDD articles please contact JDD
June 2017 534 VOLUME 16 ISSUE 6 Copyright 2017 ORIGINAL ARTICLE Journal of Drugs in Dermatology The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris Lauren K. Hoffman
More information